Prime Medicine, Inc. Equity Securities, FV-NI, Unrealized Gain (Loss)
Prime Medicine, Inc. (PRME) reported Equity Securities, FV-NI, Unrealized Gain (Loss) of $1.70 million for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-11.
Discontinued › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss · last filed 2023-05-11
- Prime Medicine, Inc. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2023-03-31 was $1.70M, a 62.07% decline year-over-year.
- Prime Medicine, Inc. equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2022-03-31 was $4.49M.
| Period end | Equity Securities, FV-NI, Unrealized Gain (Loss) 3 month |
|---|---|
| 2023-03-31 | $1.70M 10-Q · filed 2023-05-11 |
| 2022-03-31 | $4.49M 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B |